IMNN-001 (TheraPlas™-IL-12)

About IMUNON

IMUNON is a clinical-stage biotech focused on developing novel DNA-based immunotherapies and vaccines using its proprietary non-viral delivery platforms. Its strategy centers on advancing IMNN-001, a TheraPlas™-IL-12 therapy, in a Phase 2 trial for advanced ovarian cancer while concurrently validating its PlaCCine DNA vaccine platform. The company aims to overcome the limitations of viral vectors by enabling safe, localized, and durable immune stimulation for oncology and infectious disease applications.

Therapeutic Areas